



LETTER TO THE EDITOR

Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease

Chronic beryllium disease (CBD) is a granulomatous lung disorder that develops in 1–10% of beryllium-exposed workers.^{1–4} While the natural history of CBD varies, increased respiratory symptoms, worsening chest radiography and pulmonary physiology are common.^{5–9} Therapy for CBD is aimed at suppressing the beryllium-stimulated immune response, thus improving and/or stabilizing lung function. First line therapy is usually oral corticosteroids,^{10–13} with other agents, such as methotrexate, used as steroid sparing therapy.^{14–16} Despite numerous side effects, corticosteroids improve symptoms, chest radiographs and lung function in CBD. With treatment, while some patients may show a response initially, some patients with CBD worsen clinically.^{10–13} There are limited alternate treatment options available.

We report herein, the first randomized, double-blinded placebo-controlled study undertaken to assess a TNF- α inhibitor, infliximab in treatment of CBD. Because of TNF- α 's role in the initiation and perpetuation of granulomatous inflammation, we hypothesized that infliximab would result in improvement in Arterial-alveolar (A-aPaO₂) gradient after exercise (primary outcome), pulmonary function, quality of life and immune markers. The study was conducted at National Jewish Health (NJH) and the Hospital of University of Pennsylvania (HUP), based on a sarcoidosis trial.¹⁷ We aimed to enroll 20 CBD subjects^{2,8,18} on stable doses of corticosteroids and/or methotrexate, with no evidence of active or chronic infection, malignancy, other chronic disease, or past treatment with another biologic with a 3:1 infliximab:placebo ratio administered at 0, 2, 6, 12, 18 and 24 weeks. Of the 13 enrolled subjects, 8 in the infliximab treatment arm and 3 in the placebo arm completed the study, two withdrew before the first infusion before the sponsor stopped the study due to slow recruitment. Study endpoints included changes in testing from baseline to week 28 (four weeks post last infusion) in A-aPaO₂, lung function, SF-36, and blood and bronchoalveolar lavage (BAL) immune markers.

The demographics of participants were representative of a CBD population (8 males, 73% and 3 females, 27%) with a median (range) age of 56.5 (46–74) years. The three in the placebo arm were all former smokers, while only 3 of

the 8 in the treatment arm were former smokers (5 were never). The median \pm SD duration (years) of prednisone use was 5.5 ± 7.7 in the placebo group and 2.8 ± 1.6 in the treatment arm. There were no baseline differences in lung function (median \pm SD FEV1 percent predicted: 84 ± 3.92 in placebo group, 72.5 ± 5.07 in treatment group; FVC percent predicted: 85 ± 7.79 vs. 69.5 ± 4.8 ; DLCO/VA: 61 ± 6.17 vs. 71.5 ± 6.27), chest radiography, quality of life, or immune markers between the placebo and treatment group. The A-a gradient at end of exercise was higher in the placebo group (75.47 ± 19.78 vs. 31.1 ± 6.16 in the treatment group, $p = 0.014$).

CBD allows the unique opportunity to assess changes in lung inflammation with treatment. Blood and BAL cells were obtained from placebo ($n = 2$ blood, $n = 2$ BAL) and infliximab treated CBD subjects ($n = 8$ blood, $n = 5$ BAL). Infliximab treatment tended to be associated with an increase in the absolute numbers of lymphocytes/cc in blood (median \pm SD, $108 \pm 14.6 \times 10^4/\text{cc}$ vs. $170 \pm 18.5 \times 10^4/\text{cc}$; $p = 0.078$) and the blood lymphocyte percent ($p = 0.11$). The median \pm SD total BAL WBC count was reduced, 118.9×10^6 at baseline to 64.9×10^6 after infliximab treatment ($p = 0.06$) as was the WBC/cc ($p = 0.06$). In contrast to blood, a decline in the total number of BAL lymphocytes/cc was noted in the infliximab treated group (baseline median $9.9 \times 10^4/\text{cc}$ [range: 2.7–40.2] to $7.3 \times 10^4/\text{cc}$ [range: 0.8–20.9] after treatment; $p = 0.06$), along with a decline in percent lymphocytes (31% [range: 20.3–70.8] at baseline to 24% [range: 5.8–48.5]; $p = 0.06$). A decline in CD4⁺ T cells was observed along with a decline in the CD4⁺ beryllium-specific T cells expressing IFN- γ and TNF- α ($p = 0.06$). Conversely, an increase in the BAL percent macrophages was noted with infliximab treatment (58% baseline to 73%; $p = 0.06$). These changes suggest that infliximab therapy may decrease lung inflammation and the number of pathogenic, Be-responsive CD4⁺ cells recruited to the target organ. Similar to our findings, in sarcoidosis subjects treated with infliximab there was a reversal of lymphopenia and increase in peripheral blood CD4⁺ T cells.¹⁹ The mechanism by which infliximab affects cell counts in the blood and BAL is unknown. In rheumatoid arthritis (RA), infliximab treatment appeared to reverse a dysfunctional blood T_{reg} cell population, with increase in the number and ability of the cells to suppress cytokine production.^{20,21} We

have recently shown that a deficient and dysfunctional population of natural T_{reg} cells are present in the lung of CBD subjects compared to those with beryllium sensitization without disease.²²

With regard to clinical parameters explained in this study, our primary endpoint, the A-aPaO₂ proved to be technically problematic and no difference was found following infliximab treatment. No change was found in symptoms of dyspnea, FVC or chest radiograph. As the sarcoidosis trial¹⁷ noted improvement in a subgroup, we observed that those with a baseline diffusing capacity for carbon monoxide (DLCO) <80% predicted ($n = 5$, median \pm SD, 65% \pm 3.24), improved with treatment (72% \pm 1.43, $p = 0.06$). A number of studies have found DLCO to be a good marker of CBD progression^{6,7} and response to therapy.^{10,11} Our power to detect clinically significant responses was limited because of small numbers of subjects with a range of disease severity.

We observed improvements in quality of life measures with treatment. The overall SF-36 mental score for the infliximab treated group demonstrated a sustained increase of 4.6 points ($p = 0.08$), while the placebo group dropped 7.5 points. Although no change was observed in the overall physical score, a sub-component, the Bodily Pain Score improved (54 at baseline to 84, $p = 0.03$). In clinical trials of Crohn's disease^{23–26} and RA,^{26–28} infliximab-treated groups showed improvement in quality of life scores. While subjects with RA, psoriasis and ankylosing spondylitis had lower physical and mental quality of life scores than our subjects,²⁷ the changes noted after treatment with infliximab were similar for CBD. In RA, similar to our study, the greatest change was noted in bodily pain scores, suggesting that infliximab reduces systemic inflammation even in a lung disease such as CBD. It is possible that CBD activity measures do not necessarily correlate with patient-reported health-related quality of life outcomes.^{29,30} Since compliance is likely closely linked to patient's perception of health or improvement, improved SF-36 scores may inform physician–patient decisions regarding treatment options.

In summary, we describe the first clinical trial in CBD with infliximab. The study demonstrated alterations in the pulmonary immune response as a result of infliximab treatment. The mechanism by which infliximab affects this immune response is unknown, but may be more easily studied in CBD with evaluation of the specific components of a beryllium-stimulated immune response. Additionally, while our small numbers limited our ability to detect significant improvement in lung function, we observed an improvement in aspects of quality of life with treatment, and a suggestion that those with more severe gas exchange as indicated by DLCO may demonstrate clinical response.

Funding

Centocor, Inc., Malvern, Pennsylvania. This publication was supported by NIH/NCRR Colorado CTSI Grant Number 1UL1RR025780 and UL1RR024134 from the National Center for Research Resources. Its contents are the authors' sole responsibility and do not necessarily represent official NIH views.

Trial registration

Beryllium Infliximab Study: Clinical Interventional Trial (BISCIT).

ClinicalTrials.gov Identifier: NCT00111917.

Conflict of interest statement

Drs. Lisa A. Maier, Lee S. Newman, and Milt Rossman have received research grants from Centocor to support this work. As part of this grant Juliana Barnard and May Gillespie received support to conduct the work for this project. Drs. Lisa Maier and Milton Rossman also direct beryllium testing laboratories and have provided consultation in patient related medicolegal issues.

References

1. Henneberger PKG, Sandra K, Miller William E, Doney Brent, Groce Dennis W. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. *J Occup Environ Hyg* 2004;1: 648–59.
2. Samuel GM, Lisa A. Immunology of chronic beryllium disease. *Curr Opin Allergy Clin Immunol* 2008;8:126–34.
3. Schuler CRK, Michael S, Deubner David C, Berakis Michael T, McCawley Michael, Henneberger Paul K, Rossman Milton D, Kreiss Kathleen. Process-related risk of beryllium sensitization and disease in a copper–beryllium alloy facility. *Am J Ind Med* 2005;47:195–205.
4. Henneberger PKC, Debra, Deubner David D, Kent Michael S, McCawley Michael, Kreiss Kathleen. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. *Int Arch Occup Environ Health* 2001;74: 167–76.
5. Daniloff EMB, Bucher Becki, Newell Jr John D, Bernstein Steven M, Newman Lee S. Observer variation and relationship of computed tomography to severity of beryllium disease. *Am J Respir Crit Care Med* 1997;155:2047–56.
6. Duggal MD, David C, Curtis Anne M, Cullen Mark R. Long-term follow-up of beryllium sensitized workers from a single employer. *BMC Public Health* 2010;10(5):1–10.
7. Mroz MMM, Lisa A, Strand Matthew, Silviera Lori, Newman Lee S. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. *Am J Ind Med* 2009;52(10):762–73.
8. Newman LSM, Margaret M, Balkissoon Ronald, Maier Lisa A. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study. *Am J Respir Crit Care Med* 2005;171: 54–60.
9. Pappas GPN, Lee S. Early pulmonary physiologic abnormalities in beryllium disease. *Am Rev Respir Dis* 1993;148:661–6.
10. Marchand-Adam S, El Khatib A, Guillon F, et al. Short- and long-term response to corticosteroid therapy in chronic beryllium disease. *Eur Respir J* 2008;32(3):687–93.
11. Sood AB, William S, Cullen Mark R. Variable response to long-term corticosteroid therapy in chronic beryllium disease. *Chest* 2004;126(6):2000–7.
12. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. *J Am Med Assoc* 2002; 287(10):1301–7.
13. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. *Thorax* 1996;51(3):238–47.

14. Baughman RPL, Elyse E. A clinical approach to the use of methotrexate for sarcoidosis. *Thorax* 1999;**54**:742–6.
15. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. *Clin Chest Med* 1997;**18**(4):853–64.
16. Daniloff E. Methotrexate treatment in chronic beryllium disease. *Am J Respir Crit Care Med* 1998;**157**:A146.
17. Baughman RPD, Marjolein, Kavuru Mani, Judson Marc, Costabel Ulrich, du Bois Roland, Albera Carlo, Brutsche Martin, Davis Gerald, Donohue James F, Muller-Quernheim Joachim, Schlenker-Herzeg Rozsa, Flavin Susan, Hung Lo Kim, Oemar Barry, Barnatha Elliot Son behalf of the Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. *Am J Respir Crit Care Med* 2006;**174**:795–802.
18. Maier LAS, Richard T, Bauer Roslyn A, Kittle Lori A, Lympny Penny, McGrath Deirdre, Dubois Roland, Daniloff Elaine, Rose Cecile S, Newman Lee S. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. *Am J Respir Crit Care Med* 2001;**164**:1192–9.
19. Crouser ED, Julian MW, Shao G, Fox C, Hauswirth D, Jehn J, Lozanski G, Erdal S, Wewers MD. Infliximab reverses Peripheral CD4+ T cell depletion in lymphopenic sarcoidosis patients. *Am J Respir Crit Care Med* 2009;**179**:A2255.
20. Ehrenstein MRE, Jamie G, Singh Animesh, Moore Samantha, Warnes Gary, Isenberg David A, Mauri Claudia. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by ANTI-TNF alpha therapy. *J Exp Med* 2004;**200**(3):277–85.
21. Nadkarni SM, Claudia, Ehrenstein Michael R. Anti-TNF- α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF- β . *J Exp Med* 2007;**204**(1):33–9.
22. Mack DGL, Allison M, Falta Michael T, Palmer Brent E, Maier Lisa A, Fontenot Andrew P. Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects. *Am J Respir Crit Care Med* 2010;**181**:1241–9.
23. Hanauer SBL, Gary R, Mayer Lloyd F, Schreiber S, Colombel Jean Frederic, Rachmilewitz Daniel, Wolf Douglas C, Olson Allan, Bao Welhang, Rutgeerts Paul the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;**359**:1541–9.
24. Sands BEA, Frank H, Bernstein Charles N, Chey William Y, Feagan Brian G, Fedorak Richard N, Kamm Michael A, Korzenik Joshua R, Lashner Bret A, Onken Jane E, Rachmilewitz Daniel, Rutgeerts Paul, Wild Gary, Wolf Douglas C, Marsters Paul A, Travers Suzanne B, Blank Marion A, van Deventer Sander J. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004;**350**(9):876–85.
25. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. *Am J Gastroenterol* 2004;**99**(1):91–6.
26. Lipsky PEVDH, Desiree, St. Clair E William, Furst Daniel E, Breedveld Ferdinand C, Kalden Joachim, Smolen Josef S, Weisman Michael, Emery Paul, Feldmann Marc, Harriman Gregory R, Maini Ravinder for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and Methotrexate in the treatment of rheumatoid arthritis. *N Engl J Med* 2000;**343**(22):1594–602.
27. Han CS, Josef S, Kavanaugh Arthur, van der Heijde Desiree, Braun Jurgen, Westhovens Rene, Zhao Ning, Rahman Mahboob U, Baker Daniel, Bala Mohan. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. *Arthritis Res Ther* 2007;**9**(R103):1–6.
28. Kavanaugh A. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. *Ann Rheum Dis* 2005;**65**(4):471–7.
29. Contopoulos-Ioannidis DG, Karvouni A, Kouri I, Ioannidis JP. Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. *BMJ* 2009;**338**:a3006.
30. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. *Arthritis Rheum* 2003;**48**(6):1530–42.

Lisa A. Maier*

Division of Environmental and Occupational Health Sciences, Hollis Laboratory, Department of Medicine, National Jewish Health, Denver, CO, USA

Division of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado, Aurora, CO, USA

Department of Environmental and Occupational Health, Colorado School of Public Health, University of Colorado, Aurora, CO, USA

Briana Q. Barks

Margaret Mroz

Division of Environmental and Occupational Health Sciences, Hollis Laboratory, Department of Medicine, National Jewish Health, Denver, CO, USA

Milton D. Rossman

Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Juliana Barnard

May Gillespie

Division of Environmental and Occupational Health Sciences, Hollis Laboratory, Department of Medicine, National Jewish Health, Denver, CO, USA

Allison Martin

Douglas G. Mack

Division of Allergy and Clinical Immunology, Department of Medicine, School of Medicine, University of Colorado, Aurora, CO, USA

Lori Silveira

Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, CO, USA

Richard T. Sawyer

Division of Environmental and Occupational Health Sciences, Hollis Laboratory, Department of Medicine, National Jewish Health, Denver, CO, USA

Lee S. Newman

Division of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado, Aurora, CO, USA

Division of Allergy and Clinical Immunology, Department of Medicine, School of Medicine, University of Colorado, Aurora, CO, USA

*Department of Environmental and Occupational Health,
Colorado School of Public Health, University of Colorado,
Aurora, CO, USA*

*Division of Allergy and Clinical Immunology, Department of
Medicine, School of Medicine, University of Colorado,
Aurora, CO, USA*

Andrew P. Fontenot
*Integrated Department of Immunology, National Jewish
Health, Denver, CO, USA*
*Division of Pulmonary Sciences and Critical Care Medicine,
School of Medicine, University of Colorado, Aurora,
CO, USA*

*Corresponding author. National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA. Tel.: +1 303 398 1983; fax: +1 303 398 1452.
E-mail address: maierl@njhealth.org

23 April 2012